Trials / Withdrawn
WithdrawnNCT04930770
Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Maria Joyera Rodríguez · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective will be to analyze the development of cellular and humoral immunity against SARS-CoV-2 after administration of a third dose of mRNA-1273 (Moderna) vaccine in patients who have remained seronegative after the full standard (two-dose) regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MRNA-1273 | Renal or renopancreatic transplant's patient will receive a third dose of mRNA 1273 (Moderna) vaccine from 28 days after administration of the second dose and after the seronegativity has been verified. |
Timeline
- Start date
- 2021-09-01
- Primary completion
- 2021-12-01
- Completion
- 2022-03-01
- First posted
- 2021-06-18
- Last updated
- 2025-06-22
Source: ClinicalTrials.gov record NCT04930770. Inclusion in this directory is not an endorsement.